Tag: BIMZELX

UCB announces positive 48-week results for BIMZELX in Hidradenitis Suppurativa studies

businessnewstoday- March 9, 2024

At the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, UCB, a leading global biopharmaceutical company, shared promising 48-week post-hoc analyses ... Read More